Paiania, 8 November 2023 - Lavipharm S.A. announces key financial figures for the nine-month period of 2023 and business developments during third quarter: Lavipharm Key Financial Figures Q3 2023  ...

Paiania, 4 May 2023 – Group Earnings before Interest, Tax, Depreciation and Amortization (EBITDA) increased by 34% during the first quarter of 2023 and amounted to €2.46 million compared to €1.84 million during the relevant period of the previous year. Lavipharm Key Financial Figues Q1 2023...

Paiania, 27 April 2023 - Lavipharm S.A, pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, and as part of providing accurate and timely information to the investment community, announces the amended Financial Calendar of 2023. The amendment refers to the Analysts’...

Paiania, 28 March 2023 – Lavipharm S.A., according to the provisions of article 19 of the European Regulation No 596/2014 and the Regulation of the Athens Exchange, announces the appointment of Mr. Evangelos Paterakis as Chief Accountant replacing Mr. Panagiotis Pavlou, who is retiring.   ###...

Peania, 15 March 2023 - Lavipharm S.A. announces the key financial figures for 2022 and business developments in its activity: Lavipharm Flash Note FY2022 ...

Peania, 6 March 2023 - Lavipharm S.A, pursuant to articles 4.1.2 & 4.1.3.15.1 of the Athens Stock Exchange Rulebook, announces the Financial Calendar of 2023, as follows : FINANCIAL CALENDAR 2023...